Published in Proc Natl Acad Sci U S A on September 01, 1983
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
Escherichia coli gpt gene provides dominant selection for vaccinia virus open reading frame expression vectors. J Virol (1988) 4.92
Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus. EMBO J (1986) 3.89
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
One hundred base pairs of 5' flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription. Proc Natl Acad Sci U S A (1985) 3.23
Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. J Virol (1985) 3.06
Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A (1984) 2.85
Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J Exp Med (1992) 2.22
Expression of the major glycoprotein G of human respiratory syncytial virus from recombinant vaccinia virus vectors. Proc Natl Acad Sci U S A (1986) 1.85
Expression of Sindbis virus structural proteins via recombinant vaccinia virus: synthesis, processing, and incorporation into mature Sindbis virions. J Virol (1985) 1.75
Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol (2006) 1.66
Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. J Virol (1992) 1.59
Vaccinia virus vaccines: past, present and future. Antiviral Res (2009) 1.58
Anchoring a secreted plasmodium antigen on the surface of recombinant vaccinia virus-infected cells increases its immunogenicity. Mol Cell Biol (1986) 1.31
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Immune response in skunks to a vaccinia virus recombinant expressing the rabies virus glycoprotein. Can J Vet Res (1987) 1.16
Genetic determinants of resistance to ectromelia (mousepox) virus-induced mortality. J Virol (1985) 1.15
Mapping of the genes coding for the two major vaccinia virus core polypeptides. Nucleic Acids Res (1984) 1.12
Organization of RNA transcripts from a vaccinia virus early gene cluster. J Virol (1984) 1.07
Identification by a random sequencing strategy of the fowlpoxvirus DNA polymerase gene, its nucleotide sequence and comparison with other viral DNA polymerases. Nucleic Acids Res (1987) 1.06
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun (1996) 1.03
The evolution of poxvirus vaccines. Viruses (2015) 1.02
Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci U S A (1987) 0.99
Immune responses to H-2Kd antigen expressed by recombinant vaccinia virus. Proc Natl Acad Sci U S A (1986) 0.97
Failure of recombinant vaccinia viruses expressing Plasmodium falciparum antigens to protect Saimiri monkeys against malaria. Infect Immun (1991) 0.97
Response of dairy calves to vaccinia viruses that express foreign genes. J Clin Microbiol (1986) 0.93
Construction of cell lines that regulate by temperature the amplification and expression of influenza virus non-structural protein genes. EMBO J (1986) 0.92
Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence. J Gen Virol (2013) 0.90
Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence. J Gen Virol (2008) 0.89
A mechanism for the inhibition of DNA-PK-mediated DNA sensing by a virus. PLoS Pathog (2013) 0.88
Reflections on the early development of poxvirus vectors. Vaccine (2013) 0.88
Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection. J Gen Virol (2013) 0.86
Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol (2010) 0.86
Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy. J Gen Virol (2013) 0.86
CRISPR-Cas9 as a Powerful Tool for Efficient Creation of Oncolytic Viruses. Viruses (2016) 0.83
Isolation of cis-acting vaccinia virus DNA fragments promoting the expression of herpes simplex virus thymidine kinase by recombinant viruses. J Virol (1985) 0.83
Priming immunization against cholera toxin and E. coli heat-labile toxin by a cholera toxin short peptide-beta-galactosidase hybrid synthesized in E. coli. EMBO J (1985) 0.81
Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS One (2012) 0.80
Genetic engineering of antiviral agents. Antimicrob Agents Chemother (1987) 0.75
Investigating Viruses during the Transformation of Molecular Biology. J Biol Chem (2017) 0.75
Vaccinia virus recombinants expressing an 11-kilodalton beta-galactosidase fusion protein incorporate active beta-galactosidase in virus particles. J Virol (1988) 0.75
Towards a hepatitis A vaccine. A review. J Hyg (Lond) (1984) 0.75
From Biocompatibility to Immune Engineering. Exp Biol Med (Maywood) (2016) 0.75
Construction and characterization of new cloning vehicles. II. A multipurpose cloning system. Gene (1977) 114.87
A rapid boiling method for the preparation of bacterial plasmids. Anal Biochem (1981) 59.01
Prolonged incubation in calcium chloride improves the competence of Escherichia coli cells. Gene (1979) 25.53
Rat insulin genes: construction of plasmids containing the coding sequences. Science (1977) 17.05
Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A (1982) 7.81
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
A restriction map of the bacteriophage T4 genome. Mol Gen Genet (1980) 6.37
Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA. Proc Natl Acad Sci U S A (1982) 5.25
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Mapping and identification of the vaccinia virus thymidine kinase gene. J Virol (1982) 2.44
Gene composition of high-yielding influenza vaccine strains obtained by recombination. J Infect Dis (1980) 2.11
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
NYVAC: a highly attenuated strain of vaccinia virus. Virology (1992) 3.38
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Detection of major histocompatibility complex class I-restricted, HIV-specific cytotoxic T lymphocytes in the blood of infected hemophiliacs. Blood (1989) 2.37
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Vaccinia virus host range genes. Virology (1990) 2.02
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
An update on the vaccinia virus genome. Virology (1993) 1.95
Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology (1999) 1.92
Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol (1989) 1.87
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression. Gene (1986) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Antibody-dependent cell-mediated cytotoxicity directed by a human monoclonal antibody reactive with gp120 of HIV-1. AIDS (1991) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (1994) 1.51
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
High molecular weight virion-associated RNA of vaccinia. A possible precursor to 8 to 12 S mRNA. J Biol Chem (1977) 1.45
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
Computerized literature searching in a teaching family practice center. Fam Pract Res J (1991) 1.42
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res (1998) 1.38
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology (1995) 1.36
The topological mechanism of phage lambda integrase. J Mol Biol (1999) 1.36
Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product. Virology (1986) 1.35
Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine (1988) 1.35
Deletion of 55 open reading frames from the termini of vaccinia virus. Virology (1991) 1.34
Fowlpox virus as a vector in non-avian species. Vaccine (1988) 1.29
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine (1991) 1.28
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27
Housing quality among North Carolina farmworker families. J Agric Saf Health (2007) 1.26
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26
Some reasons for compliance and noncompliance in a health maintenance organization breast cancer screening program. J Compliance Health Care (1988) 1.25
Vaccinia virus as an expression vector. Methods Enzymol (1987) 1.25
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol (1991) 1.24
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24
Molecular complexity of vaccinia DNA and the presence of reiterated sequences in the genome. Virology (1977) 1.23
Physical mapping and DNA sequence analysis of the rifampicin resistance locus in vaccinia virus. Virology (1985) 1.22
Efficacy studies on a canarypox-rabies recombinant virus. Vaccine (1991) 1.20
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J Virol (1990) 1.19
Vaccinia: virus, vector, vaccine. Adv Virus Res (1988) 1.19
A randomized trial of a brief intervention to increase fruit and vegetable intake: a replication study among callers to the CIS. Prev Med (2001) 1.19
Early HIV-1 envelope-specific cytotoxic T lymphocyte responses in vertically infected infants. J Exp Med (1997) 1.19
In vitro synthesis of a high molecular weight virion-associated RNA by vaccinia. J Biol Chem (1977) 1.17
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses (1996) 1.16
Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells. Proc Natl Acad Sci U S A (1992) 1.16
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine (1995) 1.15
Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization. J Biol Chem (1974) 1.14
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
Differentiation of Toxoplasma gondii from closely related coccidia by riboprint analysis and a surface antigen gene polymerase chain reaction. Am J Trop Med Hyg (1993) 1.11
Sarcocystis neurona n. sp. (Protozoa: Apicomplexa), the etiologic agent of equine protozoal myeloencephalitis. J Parasitol (1991) 1.09
Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int (1993) 1.07
Equine herpesvirus type 1 unique short fragment encodes glycoproteins with homology to herpes simplex virus type 1 gD, gI and gE. J Gen Virol (1990) 1.07
Mutations in ORF D13L and other genetic loci alter the rifampicin phenotype of vaccinia virus. Virology (1993) 1.06
Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol (1990) 1.05
Regeneration of corticospinal axons in the rat. Ann Neurol (1977) 1.05
A DNA ligase gene in the Copenhagen strain of vaccinia virus is nonessential for viral replication and recombination. Virology (1990) 1.05